zur Navigation zum Inhalt


© Syda Productions / fotolia.com

Tropfen Blut zur Tumor-Diagnostik

05/2015 Zirkulierende zellfreie Tumor-DNA: Möglichkeiten und Grenzen einer Therapiesteuerung.

Bereits seit 1948 ist die Existenz von im Blut zirkulierender zellfreier DNA (cfDNA) bekannt. Allerdings dauerte es Jahrzehnte, bis ihr klinischer Nutzen als potenzieller Biomarker in der Onkologie erkannt wurde. Die sogenannte „Liquid Biopsy“ ist ein vielversprechendes Konzept, um wiederholt genetische Follow-Up-Daten von Tumorpatienten zu erheben. [...]

Mehr zum Thema

<< Seite 1 >>

Tailoring treatment in myeloma: are there clues from biology?

05/2015 Cytogenetic data have established relevance for prognostication in myeloma. Also, certain chromosomal aberrations were associated with an increased risk of progression of smoldering myeloma to active disease. The impact of cytogenetic and molecular data on treatment decisions is however limited. [...]

Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients

05/2015 During the course of disease multiple myeloma subclones acquire more and more additional genetic changes causing an aggressive proliferative growth with less responsiveness to therapeutic agents. On the other hand new therapeutic options are getting available, leading to the question, if a more intensive treatment in newly diagnosed myeloma patients may result in a better outcome concerning progression-free survival, quality of life and overall survival. [...]

Lymphoma: anything new?

05/2015 In the recent years, the armamentarium for the treatment of hematological malignancies has been substantially enriched by the implementation of novel classes of drugs that target specific signaling or metabolic pathways and/or the microenvironment of the malignant cells. [...]

Optimal follow-up of cervical cancer patients

05/2015 Gynecological malignancies account for round 10 % of all female cancers, with the cervical cancer being one of the major women health problems in developing regions of the world. Surveillance programs of cervical cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for curing patients with recurrence. [...]

Optimal follow-up of endometrial cancer patients

05/2015 Gynecological malignancies account round 10 % of all female cancers, with the uterine cancer being the most predominant one. Surveillance programs of all gynecologic cancers are primarily based on recurrence rates, timing of recurrence, salvage options and chances for cure of patient with recurrence. [...]

Beyond R-CHOP: treatment of double hit, triple hit, MYC + NHL?

05/2015 Double hit (DH) are defined as MYC and BCL2 or/and BCL6 coexpressing B-cell lymphomas. Morphologically they are found in the diffuse large B-cell lymphoma (DLBCL) or in the group of B-cell lymphoma, unclassifiable, with features between DLBCL and Burkitt lymphoma (BCLU). [...]

Medizin heute

Aktuelle Printausgaben